Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1,3-dimethyl-6-((2-(n-(2-hydroxyethyl)-3-(4-nitrophenyl)propylamino)ethylamino)-2,4(1h),3h)-pyrimidinedione Hydrochloride
2. Ms 551
3. Ms-551
4. Nifekalant
1. 130656-51-8
2. Nifekalant
3. Nifekalant Hcl
4. Ms 551
5. Ms-551
6. 130636-43-0
7. Tpp5r0mdqs
8. Shinbit
9. Dsstox_cid_26495
10. Dsstox_rid_81665
11. Dsstox_gsid_46495
12. 6-[2-[2-hydroxyethyl-[3-(4-nitrophenyl)propyl]amino]ethylamino]-1,3-dimethylpyrimidine-2,4-dione;hydrochloride
13. Nifekalant Hydrochloride (jan)
14. Smr000466369
15. Cas-130636-43-0
16. Unii-tpp5r0mdqs
17. Ncgc00164637-01
18. Shinbit (tn)
19. 1,3-dimethyl-6-((2-(n-(2-hydroxyethyl)-3-(4-nitrophenyl)propylamino)ethylamino)-2,4(1h),3h)-pyrimidinedione Hcl
20. Mls000759497
21. Mls001401449
22. Mls006010783
23. Schembl243693
24. Chembl553090
25. Dtxsid7048374
26. Chebi:31909
27. Hy-b0772a
28. 2,4(1h,3h)-dione Hydrochloride
29. Bcp12511
30. Tox21_112254
31. Nifekalant Hydrochloride [mi]
32. Akos015900502
33. Tox21_112254_1
34. Ac-3499
35. Ccg-100897
36. Nc00147
37. Ncgc00164637-02
38. Nifekalant Hydrochloride [who-dd]
39. 2,4(1h,3h)-pyrimidinedione, 6-((2-((2-hydroxyethyl)(3-(4-nitrophenyl)propyl)amino)ethyl)amino)-1,3-dimethyl-, Monohydrochloride
40. Amino)ethylamino)-1,3-dimethylpyrimidine-
41. Nifekalant Hydrochloride, >=98% (hplc)
42. Db-041979
43. Cs-0014293
44. Ft-0631132
45. D01856
46. 656n518
47. A806121
48. 6-(2-((2-hydroxyethyl)(3-(4-nitrophenyl)propyl)
49. J-005843
50. Q27290131
51. Benzoic Acid,4-(2-aminoethyl)-,1,1-dimethylethyl Ester
52. 6-(2-((2-hydroxyethyl)(3-(4-nitrophenyl)propyl)amino)ethylamino)-1,3-dimethylpyrimidine-2,4(1h,3h)-dione Hydrochloride
53. 6-(2-(2-hydroxyethyl-(3-(4-nitrophenyl)propyl)amino)ethyl Amino)-1,3-dimethylpyrimidine-2,4-dione Hcl
| Molecular Weight | 441.9 g/mol |
|---|---|
| Molecular Formula | C19H28ClN5O5 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 10 |
| Exact Mass | 441.1778967 g/mol |
| Monoisotopic Mass | 441.1778967 g/mol |
| Topological Polar Surface Area | 122 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 613 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Anti-Arrhythmia Agents
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)
ABOUT THIS PAGE
A Nifekalant Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nifekalant Hydrochloride, including repackagers and relabelers. The FDA regulates Nifekalant Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nifekalant Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Nifekalant Hydrochloride supplier is an individual or a company that provides Nifekalant Hydrochloride active pharmaceutical ingredient (API) or Nifekalant Hydrochloride finished formulations upon request. The Nifekalant Hydrochloride suppliers may include Nifekalant Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Nifekalant Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Nifekalant Hydrochloride Drug Master File in Japan (Nifekalant Hydrochloride JDMF) empowers Nifekalant Hydrochloride API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Nifekalant Hydrochloride JDMF during the approval evaluation for pharmaceutical products. At the time of Nifekalant Hydrochloride JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Nifekalant Hydrochloride suppliers with JDMF on PharmaCompass.
Nifekalant Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nifekalant Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nifekalant Hydrochloride GMP manufacturer or Nifekalant Hydrochloride GMP API supplier for your needs.
A Nifekalant Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Nifekalant Hydrochloride's compliance with Nifekalant Hydrochloride specifications and serves as a tool for batch-level quality control.
Nifekalant Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Nifekalant Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nifekalant Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Nifekalant Hydrochloride EP), Nifekalant Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nifekalant Hydrochloride USP).
LOOKING FOR A SUPPLIER?
